The immune system fights bacteria, viruses and other pathogens by utilizing several types of T cells, all of which have receptors that are specific to particular antigens. On killer T cells, the receptor works in concert with three signaling modules and a coreceptor to destroy the infected cell. A new study has found that a novel T cell genetically engineered by a team of University of Arizona researchers including Dr. Michael Kuhns, associate professor in the UArizona College of Medicine – Tucson Department of Immunobiology and BIO5 member, is able to target and attack pathogenic T cells that cause Type 1 diabetes, which could lead to new immunotherapy treatments.
Related
